EA202090383A1 - Усовершенствованный способ получения производных аминопиримидина - Google Patents

Усовершенствованный способ получения производных аминопиримидина

Info

Publication number
EA202090383A1
EA202090383A1 EA202090383A EA202090383A EA202090383A1 EA 202090383 A1 EA202090383 A1 EA 202090383A1 EA 202090383 A EA202090383 A EA 202090383A EA 202090383 A EA202090383 A EA 202090383A EA 202090383 A1 EA202090383 A1 EA 202090383A1
Authority
EA
Eurasian Patent Office
Prior art keywords
producing
improved method
aminopyrimidine derivatives
preparation
protein kinases
Prior art date
Application number
EA202090383A
Other languages
English (en)
Inventor
Санг-Хо Ох
Дза-Хеоук Кхоо
Дзонг-Чул Лим
Сеонг-Ран Ли
Хиун Дзу
Ву-Сеоб Шин
Дае-Гиу Парк
Су-Мин Парк
Йоон-Ах Хванг
Original Assignee
Юхан Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65040211&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202090383(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юхан Корпорейшн filed Critical Юхан Корпорейшн
Publication of EA202090383A1 publication Critical patent/EA202090383A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/22—Tin compounds
    • C07F7/2284—Compounds with one or more Sn-N linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

В настоящем изобретении предложен усовершенствованный способ получения производного аминопиримидина или его фармацевтически приемлемой соли, имеющих селективную ингибирующую активность в отношении протеинкиназ, особенно в отношении протеинкиназ для мутантных рецепторов эпидермального фактора роста. Кроме того, в настоящем изобретении обеспечены новые промежуточные соединения, используемые в указанном способе, и способы их получения.
EA202090383A 2017-07-28 2018-07-25 Усовершенствованный способ получения производных аминопиримидина EA202090383A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170096212 2017-07-28
PCT/KR2018/008379 WO2019022485A1 (en) 2017-07-28 2018-07-25 IMPROVED PROCESS FOR THE PREPARATION OF AMINOPYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
EA202090383A1 true EA202090383A1 (ru) 2020-06-15

Family

ID=65040211

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090383A EA202090383A1 (ru) 2017-07-28 2018-07-25 Усовершенствованный способ получения производных аминопиримидина

Country Status (31)

Country Link
US (4) US10889578B2 (ru)
EP (1) EP3658552B1 (ru)
JP (2) JP7228562B2 (ru)
KR (1) KR20190013553A (ru)
CN (2) CN116987112A (ru)
AU (2) AU2018308038B2 (ru)
BR (1) BR112020001278A2 (ru)
CA (1) CA3070069C (ru)
CO (1) CO2020000374A2 (ru)
DK (1) DK3658552T3 (ru)
EA (1) EA202090383A1 (ru)
ES (1) ES2962961T3 (ru)
FI (1) FI3658552T3 (ru)
HR (1) HRP20231191T1 (ru)
HU (1) HUE063533T2 (ru)
IL (2) IL271973B (ru)
LT (1) LT3658552T (ru)
MA (1) MA49700B1 (ru)
MD (1) MD3658552T2 (ru)
MX (1) MX2022008743A (ru)
NZ (1) NZ761156A (ru)
PH (1) PH12020500059A1 (ru)
PL (1) PL3658552T3 (ru)
PT (1) PT3658552T (ru)
RS (1) RS64654B1 (ru)
SA (1) SA520411112B1 (ru)
SG (1) SG11201913517UA (ru)
SI (1) SI3658552T1 (ru)
UA (1) UA125317C2 (ru)
WO (1) WO2019022485A1 (ru)
ZA (1) ZA202001250B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3658552T3 (fi) 2017-07-28 2023-11-16 Yuhan Corp Menetelmä n-(5-((4-(4-((dimetyyliamino)metyyli)-3-fenyyli-1h-pyratsol-1-yyli)pyrimidin-2-yyli)amino)-4-metoksi-2-morfolinofenyyli)akryyliamidin valmistamiseksi saattamalla vastaava amiini reagoimaan 3-halopropionyylikloridin kanssa
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
ATE370123T1 (de) 2001-11-27 2007-09-15 Wyeth Corp 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト ＪＡＫ阻害剤およびＢｃｒ−Ａｂｌ、Ｆｌｔ−３、ＦＡＫまたはＲＡＦキナーゼ阻害剤のうち少なくとも１個の組合せ
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
EP2684874B1 (en) 2006-10-23 2017-05-17 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
KR20110025224A (ko) 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. 헤테로아릴 화합물 및 이의 용도
NZ599826A (en) 2009-10-12 2014-08-29 Myrexis Inc Amino-pyrimidine compounds as inhibitors of ikk epsilon and/or tbk1
KR101663637B1 (ko) 2009-11-13 2016-10-07 제노스코 키나아제 억제제
CA2782684C (en) 2009-12-04 2018-09-04 Mustapha Haddach Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
EA022623B1 (ru) 2010-10-06 2016-02-29 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные бензимидазола в качестве ингибиторов pi3-киназ
ES2635713T3 (es) 2010-11-01 2017-10-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
WO2012082689A1 (en) 2010-12-13 2012-06-21 Array Biopharma Inc. SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
CN105348266B (zh) * 2011-07-27 2018-04-10 阿斯利康(瑞典)有限公司 取代的3‑氯‑n‑[3‑(嘧啶‑2‑基氨基)苯基]丙酰胺或其盐
WO2013096642A1 (en) 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
PL2797927T3 (pl) 2011-12-30 2019-12-31 Hanmi Pharm. Co., Ltd. Pochodne tieno[3,2-d]pirymidyny wykazujące działanie hamujące kinazy białkowe
CN104860891B (zh) 2014-02-25 2017-06-30 上海海雁医药科技有限公司 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物
CN106687457B (zh) 2014-05-13 2020-01-10 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
CN111875585B (zh) 2014-06-12 2023-06-23 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
PT3207035T (pt) * 2014-10-13 2020-02-19 Yuhan Corp Compostos e composições para modular actividades da cinase do mutante de egfr
CN104788427B (zh) 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
AR102263A1 (es) 2015-10-14 2017-02-15 Yuhan Corp Compuestos y composiciones para la modulación de las actividades quinasa del receptor de egf mutante
DE102017212159A1 (de) 2017-07-14 2019-01-17 Krones Aktiengesellschaft Verfahren und Vorrichtung zur Handhabung von Stückgütern, Artikeln und/oder Gebinden
PT3658547T (pt) 2017-07-28 2023-10-20 Yuhan Corp Processo de preparação de n -(5 -(4 -(4 -formil -3- fenil- 1h -pirazol- 1 -il)pirimidin -2- ilamino) -4 -metoxi 2- morfolinofenil) acrilamida
FI3658552T3 (fi) 2017-07-28 2023-11-16 Yuhan Corp Menetelmä n-(5-((4-(4-((dimetyyliamino)metyyli)-3-fenyyli-1h-pyratsol-1-yyli)pyrimidin-2-yyli)amino)-4-metoksi-2-morfolinofenyyli)akryyliamidin valmistamiseksi saattamalla vastaava amiini reagoimaan 3-halopropionyylikloridin kanssa
CN108826170A (zh) 2018-06-26 2018-11-16 深圳市远润欣电子有限公司 局部全般照明的模式、控制方法及台灯

Also Published As

Publication number Publication date
EP3658552A1 (en) 2020-06-03
SG11201913517UA (en) 2020-02-27
SA520411112B1 (ar) 2022-02-21
CA3070069A1 (en) 2019-01-31
HUE063533T2 (hu) 2024-01-28
US20210269427A1 (en) 2021-09-02
US20230312545A1 (en) 2023-10-05
EP3658552A4 (en) 2021-06-23
ES2962961T3 (es) 2024-03-22
US20200165236A1 (en) 2020-05-28
IL292429B2 (en) 2023-09-01
MA49700B1 (fr) 2023-09-27
NZ761156A (en) 2024-01-26
US11708362B2 (en) 2023-07-25
FI3658552T3 (fi) 2023-11-16
SI3658552T1 (sl) 2023-11-30
CO2020000374A2 (es) 2020-05-05
DK3658552T3 (da) 2023-11-20
BR112020001278A2 (pt) 2020-07-21
UA125317C2 (uk) 2022-02-16
PT3658552T (pt) 2023-11-03
CA3070069C (en) 2024-02-20
MX2022008743A (es) 2023-02-02
JP2023027091A (ja) 2023-03-01
LT3658552T (lt) 2023-11-27
AU2022202936B2 (en) 2023-04-27
MD3658552T2 (ro) 2024-02-29
CN111315742B (zh) 2023-09-01
AU2022202936A1 (en) 2022-05-26
US10889578B2 (en) 2021-01-12
RS64654B1 (sr) 2023-10-31
IL271973A (en) 2020-02-27
KR20190013553A (ko) 2019-02-11
CN111315742A (zh) 2020-06-19
CN116987112A (zh) 2023-11-03
IL292429A (en) 2022-06-01
AU2018308038B2 (en) 2022-02-03
MA49700A (fr) 2021-03-17
JP7228562B2 (ja) 2023-02-24
WO2019022485A1 (en) 2019-01-31
US11286253B2 (en) 2022-03-29
JP2020528440A (ja) 2020-09-24
HRP20231191T1 (hr) 2024-02-02
US20220281861A1 (en) 2022-09-08
PL3658552T3 (pl) 2024-02-19
IL292429B1 (en) 2023-05-01
EP3658552B1 (en) 2023-09-13
PH12020500059A1 (en) 2020-09-28
AU2018308038A1 (en) 2020-01-30
ZA202001250B (en) 2023-04-26
IL271973B (en) 2022-08-01

Similar Documents

Publication Publication Date Title
EA202090383A1 (ru) Усовершенствованный способ получения производных аминопиримидина
NZ750290A (en) Amino pyrimidine ssao inhibitors
MX2018000777A (es) Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
EA201991055A1 (ru) СПОСОБ ПОЛУЧЕНИЯ ПИРАЗОЛ[1,5-a]ПИРИМИДИНОВ И ИХ СОЛЕЙ
EA202090384A1 (ru) Промежуточные соединения, используемые для синтеза селективного ингибитора протеинкиназы, и способы их получения
EP4273132A3 (en) Processes for preparing acc inhibitors and solid forms thereof
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
NZ740616A (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
CA2983481A1 (en) Janus kinase inhibitor
EA201992474A2 (ru) Агонисты 5ht для лечения нарушений
SG10201902598VA (en) Peptidomimetic macrocycles and formulations thereof
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
CU24208B1 (es) Sal de diclorhidrato de 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y método de preparación de la misma
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
PH12020550143A1 (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors
EP4234547A3 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
MX2020010618A (es) Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
EP3560931A4 (en) METHOD FOR PRODUCING A 7H-PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE, AND CO-CRYSTAL OF SAID DERIVATIVE
EA201992516A1 (ru) Способ получения бифункциональных белков и их производных
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
MX2021007247A (es) Derivados de rapamicina.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
EA202090385A1 (ru) Новые промежуточные соединения, используемые для синтеза производных аминопиримидина, способ их получения и способ получения производных аминопиримидина с их использованием
JOP20220042A1 (ar) طرق لعلاج فرط فينيل ألانين الدم
EP3802525A4 (en) Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof